BioVaxys Technology ( ($TSE:BIOV) ) just unveiled an announcement. BioVaxys’ 2025 corporate review highlights the integration of the DPX platform ...

BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious ...

The MarketWatch News Department was not involved in the creation of this content. -- Pipette tip-based (INTip(TM)) products and workflows for nucleic acid extraction, size selection and PCR cleanup ...

$2.65 billion transaction combines the capabilities and expertise of Patheon and DSM Pharmaceutical Products to create industry powerhouse Durham, N.C. — (March 11, 2014)—DPx Holdings B.V. (DPx), ...

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against ...

Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent ...

The novel lipid-in-oil delivery platform showed positive results across multiple disease states. BioVaxys Technology Corp announced key findings from its research into the use of novel lipid-in-oil ...

Once you start toting a knife in your EDC, you’ll wonder how you ever lived without it. Cutting, prying, and oh-so-important meat-slicing — you’ve never had it so good. There are plenty of fantastic ...

JLL Partners (JLL), the middle-market private equity firm, and Royal DSM (Euronext:DSM KON), the global Life Sciences and Materials Sciences company, today announced the successful closing of the ...